Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder: Changes in Weight With Long-Term Treatment
J Clin Psychiatry 2000;61:863-867
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The effects of extended selective
serotonin reuptake inhibitor (SSRI) treatment on weight are not
well characterized. Also unknown is whether different agents have
differential effects. To examine these questions, we assessed
weight changes in patients randomly assigned to long-term
treatment with fluoxetine, sertraline, or paroxetine.
Method: Patients (N = 284) with major depressive
disorder (DSM-IV) were randomly assigned to double-blind
treatment with fluoxetine (N = 92), sertraline, (N = 96), or
paroxetine (N = 96) for a total of 26 to 32 weeks. The mean
percent change in weight was compared for each group, as was the
number of patients who had >= 7% weight increase from
Results: Patients (fluoxetine, N = 44;
sertraline, N = 48; paroxetine, N = 47) who completed the trial
were included in these analyses. Paroxetine-treated patients
experienced a significant weight increase, fluoxetine-treated
patients had a modest but nonsignificant weight decrease, and
patients treated with sertraline had a modest but nonsignificant
weight increase. The number of patients whose weight increased
>= 7% from baseline was significantly greater for
paroxetine-treated compared with either fluoxetine-treated or
Conclusion: Risk of weight gain during extended
SSRI treatment differs depending on which SSRI is used.